secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001213900-26-036448
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper posts Q4 net loss $9.1M; cash $28.7M; appoints new CEO; reports positive CSU/asthma data
--------------------------------------------------------------------------------

- Jeet Mahal named President and CEO to lead next phase of clinical growth.
- Positive CSU data: 67% complete response in BEACON Cohort 9.1; 75% in open-label extension at 12 weeks.
- Preliminary asthma data from ETESIAN study shows reduced airway hyperresponsiveness after single 180mg dose.
- Internal investigation found no drug product issues; KOL panel recommends enhanced site selection and screening.
- Q4 2025 net loss $9.1M; year net loss $75.8M; cash and equivalents $28.7M at Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026036448/0001213900-26-036448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026036448/ea0283364-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-036448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer